• Phase 1 clinical trial to begin in 2024
Biological Drug Product, Formulation, mAb Formulation
Dupilumab (Dupixent®) biosimilar
Related products
-
FormulationIsoflurane Inhalation
-
Biological Drug Product
Bevacizumab (BAT1706/AVZIVI®)
-
Biological Drug ProductSemaglutide Injection(Ozempic)
Indications:Glycemic Control
USA, EU, China approval single dose
-
